歌禮丙肝創新藥戈諾衛進入天津醫保按人頭付費試點

By PR Newswire on 26 Sep 2018

PR Newswire (www.prnasia.com), a Cision company, is the premier global provider of media monitoring platforms and news distribution services that marketers, corporate communicators and investor relations professionals leverage to engage key audiences. Having pioneered the commercial news distribution industry since 1954, PR Newswire today provides end-to-end solutions to produce, distribute, target and measure text and multimedia content across traditional, digital, mobile and social channels. Combining the world's largest multi-channel content distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire powers the stories of organizations around the world. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa and Asia-Pacific regions.

中國杭州和紹興2018年9月26日電 /美通社/ -- 歌禮製藥有限公司（歌禮製藥 1672.HK）今日宣佈，戈諾衛^®（達諾瑞韋）進入天津市人力資源和社會保障局的「基本醫療保險丙型肝炎門診醫療費用按人頭付費試點」藥品報銷範圍。此次在天津率先取得突破，標誌著戈諾衛^®正式開始進入中國省級基本醫療報銷體系。

戈諾衛^®是歌禮開發的我國第一個具有自主知識產權的、用於慢性丙型肝炎治療的口服小分子創新藥物，也是首個獲批上市的本土丙肝治療創新藥物。在中國大陸地區完成的III期臨床試驗結果顯示，經過12周治療，在基因1型非肝硬化患者中治癒率（SVR12）達97%。

「感謝天津臨床和醫保部門對本土創新藥的信任和支持，戈諾衛^®進入醫保支付體現了專家對戈諾衛^®療效和安全性的認可及政府對創新藥的支持，」歌禮創始人、董事長及總裁吳勁梓博士說，「天津醫保按人頭付費試點工作踐行了按價值付費的理念。我們希望能以天津為起點，充分發揮丙肝可治癒，醫保可控費，療效確切，和治療週期短的優勢，讓戈諾衛^®在更多地方進入醫保報銷，讓更多的中國患者受益於優秀的本土創新成果。」